Top 10 AI-Powered Biotech Stocks to Buy Right Now

7. Tyra Biosciences, Inc. (NASDAQ:TYRA)

Number of Hedge Fund Holders: 29

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the best biotech stocks on this list.

TheFly reported on April 15 that Guggenheim Securities initiated coverage of TYRA with a Buy rating and set a price target of $54. The firm highlighted the company’s lead drug candidate, dabogratinib, as a promising asset positioned to evaluate multiple clinical hypotheses across distinct patient groups. It noted that successful outcomes in even one of these settings could create meaningful upside potential for the stock. The analysis also suggested that the therapy may show utility at lower dosing levels across several disease areas, supporting its broader development potential in different indications.

In a significant operational development, on April 17, Tyra Biosciences, Inc. (NASDAQ:TYRA) announced the addition of Habib Dable to its Board of Directors. He brings over three decades of experience in the global biopharmaceutical industry, including leadership roles focused on building and scaling major specialty medicine franchises and guiding companies through periods of significant growth.

His background includes senior executive positions at Bayer and service as CEO of Acceleron Pharma, where he oversaw substantial expansion leading up to its acquisition by Merck. The company emphasized that his expertise in global product strategy and commercialization will support the advancement of its FGFR3-targeted pipeline, including dabogratinib, as it moves toward broader clinical and commercial development.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is an AI-enabled precision biotechnology company focused on FGFR-targeted therapies for cancer and genetic diseases. It uses its SNÅP platform to accelerate drug design and develop therapies for oncology and FGFR-driven conditions.